Novocure

Novocure, established in 2000, is a Jersey-based oncology company specializing in the development, manufacturing, and commercialization of Tumor Treating Fields (TTFields) therapy for solid tumors. This non-invasive treatment uses electric fields to disrupt cancer cell division. Novocure markets its flagship product, Optune, and the NovoTTF-100L delivery system, primarily for glioblastoma treatment. The company is also advancing products in clinical trials for various solid tumors, including brain metastases, lung, pancreatic, and ovarian cancers. Novocure collaborates with MSD and NYU Grossman School of Medicine for clinical and preclinical development projects. Its revenue primarily comes from the United States, with additional contributions from Germany, Japan, and other markets.

William F. Doyle

Director

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.